Revvity, Inc.

Revvity, Inc.

130.60
EUR
-9.40
(-6.71%)
1.99EPS
Feb 04Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
19.16
18.4
18.79
19.3
20.45
25.12
25.95
23.76
30.32
26.22
22.06
22.84
24.51
26.32
Basic EPS, GAAP
1.48
1.4
1.9
2.14
2.65
2.15
2.05
6.49
7.47
4.51
5.56
2.24
2.07
2.27
Free Cash Flow per Basic Share
1.41
2.5
2.56
3.2
2.61
2.81
3.23
7.96
11.18
5.38
0.73
5.21
5
5.87
Dividend per Share
0.28
0.28
0.28
0.28
0.28
0.28
0.28
0.28
0.26
0.28
0.28
0.29
0.28
0.28
Book Value per Share
17.71
18.16
18.84
19.65
22.68
23.37
25.32
33.33
56.57
58.46
63.79
63.55
64.57
65.14
Tangible Book Value per Share
-5.41
-6.51
-5.46
-4.69
-16.73
-14.17
-14.22
-9.61
-26.2
-19.6
-13.64
-11.92
-15.23
-13.03
Basic Weighted Avg Shares
113
112
112
110
110
111
111
112
126
126
125
121
117
112
Sales/Revenue/Turnover
2,158
2,070
2,105
2,116
2,257
2,778
2,884
2,663
3,828
3,312
2,751
2,755
2,856
2,942
Operating Margin (%)
12.14
8.62
12.57
14.17
13.66
12.06
13.57
32.56
32.88
22.43
10.93
12.59
12.49
12.6
Depreciation Expense
127
110
105
100
105
181
214
202
311
427
432
428
405
413
Net Income, GAAP
167
158
212
234
293
238
228
728
943
569
693
270
241
253
Effective Tax Rate (%)
- -
- -
9.59
11.62
47.12
7.84
3.96
21.19
26.1
21.35
1.9
10.46
10.58
10.61
Profit Margin (%)
7.75
7.62
10.09
11.08
12.97
8.56
7.89
27.33
24.64
17.19
25.2
9.81
8.45
8.61
Working Capital
442
471
472
587
249
463
612
587
1,227
1,744
1,551
1,697
909
1,160
LT Debt
932
1,045
1,012
1,045
1,789
1,877
2,210
1,798
5,127
4,093
3,311
3,302
2,779
2,765
Total Equity
1,994
2,042
2,110
2,154
2,503
2,585
2,814
3,735
7,141
7,383
7,873
7,667
7,250
7,271
Return on Invested Capital (%)
- -
- -
7.29
8.22
4.05
6.61
7.24
12.26
10.09
4.79
2.45
2.69
2.93
3.2
Return on Capital (%)
- -
- -
7.95
8.57
8.19
6.67
6.05
13.91
11.16
5.36
6.61
3.11
2.99
2.99
Return on Common Equity (%)
8.5
7.82
10.23
10.99
12.57
9.35
8.43
22.23
17.34
7.84
9.09
3.48
3.23
3.46

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
576
572
- -
LT Borrowings
2,632
2,633
2,634
LT Finance Leases
142
136
131
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
112
112
112
Market Capitalization
- -
- -
- -

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,128
2,298
1,861
Cash, Cash Equivalents & STI
860
1,023
593
Accounts Receivable, Net
691
709
687
Inventories
388
379
389
Total Current Liabilities
1,239
1,276
701
Payables & Accruals
663
704
701
ST Debt
576
572
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.63%
18.63%
-5.43%
Free Cash Flow
67.73%
100.18%
-7.22%
Net Income, GAAP
17.19%
-12.02%
-10.79%
Sales/Revenue/Turnover
4.36%
3.43%
3.67%
Total Cash Common Dividend
0.45%
1.11%
-4.8%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
650
692
684
729
2,755
2025
665
720
699
772
2,856
2026
711
730
729
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.21
0.45
0.77
0.78
2.24
2025
0.35
0.46
0.4
0.88
2.07
2026
0.36
0.46
0.56
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.07
0.07
0.07
0.29
2025
0.07
0.07
0.07
0.07
0.28
2026
0.07
0.07
0.07
- -
- -

Company Description

CEO
Prahlad Ramadhar Singh
Full Time Employees
11,000
Sector
Health technology
Industry
Medical specialties
Address
77 4th Avenue Waltham MA United States 02451
IPO Date
Jul 6, 1965
Business
Revvity, Inc. is a life sciences and diagnostics company that provides health science solutions, technologies, expertise, and services delivering comprehensive workflows from discovery to development, diagnosis, and cure. The company offers instruments, reagents, assay platforms, software, detection and imaging technologies, and automated solutions such as liquid handlers and cell counters. Its product portfolio includes specialized brands like AlphaLISA and SureFire Ultra no-wash assays, Cellometer and Celigo automated cell counters, chemagic nucleic acid extraction systems, IVIS fluorescence and bioluminescence imaging platforms, LentiBOOST for lentiviral transduction, Vanadis noninvasive prenatal testing systems, and various other reagents, consumables, and assay kits targeting life science research and clinical diagnostics markets. Revvity’s diagnostics segment focuses on reproductive health, immunodiagnostics, applied genomics, and infectious disease detection, serving hospitals, medical labs, clinicians, and research professionals globally. Founded in 1937 and headquartered in Waltham, Massachusetts, Revvity emerged in 2023 following the split of PerkinElmer, Inc., retaining the life sciences and diagnostics businesses while the remaining segments were sold to private equity. Since its spinoff, Revvity has undergone significant strategic restructuring, including reorganizing its operating model effective fiscal year 2025 to integrate its Applied Genomics business into a newly formed Life Sciences Solutions unit. The company re-segmented its operations into Life Sciences Solutions and Software, and Diagnostics, which now encompasses Immunodiagnostics and Reproductive Health. Recent innovations include the launch of AI-driven software platforms like Signals One, the IDS i20 ChLIA analyzer, and advanced imaging systems such as the Quantum GX3 targeting specialized diagnostics markets. Revvity actively pursues cost discipline and operational synergies while investing in digital transformation and AI integration to enhance productivity and competitive positioning in precision diagnostics and life sciences research. Revvity serves pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and clinical markets worldwide. Its comprehensive offerings support translational multi-omics technologies, biomarker identification, molecular imaging, immunoassays, molecular diagnostics, and genomic workflows with a focus on oncology, immunology, personalized medicine, and early disease detection. The company operates across North America, Europe, and other global regions, driven by innovation in reproductive health science, immune system disorder diagnostics, and genetic disorder testing. With a workforce exceeding 11,000 employees, Revvity continues to expand its product portfolio and technological capabilities to remain a leader in biotechnology, diagnostics, and life sciences markets.

Company News

  • Revvity to Showcase Strategy for Powering Scientific Intelligence at 2026 Investor Day

  • NVIDIA (NASDAQ:NVDA) Stock Sale Disclosed by Rep. Gilbert Ray Cisneros, Jr.

  • ELV or RVTY: Which Is the Better Value Stock Right Now?

  • All You Need to Know About Revvity (RVTY) Rating Upgrade to Buy

  • Madison Mid Cap Fund Q3 2026 Portfolio Activity

  • Revvity Q3 Earnings Call Highlights

  • Revvity, Inc. (RVTY) Q3 2026 Earnings Call Transcript

  • RVTY Q3 Earnings Beat Estimates on Life Sciences Strength, '26 View Up

  • Revvity Faced Off With 'Elevated Investor Expectations' — And Won

  • Revvity (RVTY) Tops Q3 Earnings and Revenue Estimates

  • Revvity Announces Financial Results for the Third Quarter of 2026

  • Revvity Board Declares Quarterly Dividend

  • Revvity Gears Up to Post Q3 Earnings: What's in Store for the Stock?

  • GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth

  • Diamond Hill Small-Mid Cap Fund Q3 2026 Contributors And Detractors

  • Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report?

  • Revvity (RVTY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

  • ELV vs. RVTY: Which Stock Is the Better Value Option?

  • Revvity Launches Signals LabGistics to Coordinate Scientific Workflows

  • Revvity: A Diagnostics Annuity Is Quietly Funding An AI Data Engine